These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 26177352

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
    Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Weber J, Kitchen VS.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr 01; 17(4):327-31. PubMed ID: 9525433
    [Abstract] [Full Text] [Related]

  • 4. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
    Catalone BJ, Kish-Catalone TM, Budgeon LR, Neely EB, Ferguson M, Krebs FC, Howett MK, Labib M, Rando R, Wigdahl B.
    Antimicrob Agents Chemother; 2004 May 01; 48(5):1837-47. PubMed ID: 15105142
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preclinical assessment of the proinflammatory potential of microbicide candidates.
    Doncel GF, Chandra N, Fichorova RN.
    J Acquir Immune Defic Syndr; 2004 Oct 01; 37 Suppl 3():S174-80. PubMed ID: 16419269
    [Abstract] [Full Text] [Related]

  • 8. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.
    Trifonova RT, Pasicznyk JM, Fichorova RN.
    Antimicrob Agents Chemother; 2006 Dec 01; 50(12):4005-10. PubMed ID: 17030562
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety.
    Lozenski K, Ownbey R, Wigdahl B, Kish-Catalone T, Krebs FC.
    BMC Pharmacol Toxicol; 2012 Oct 01; 13():9. PubMed ID: 23025553
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC.
    AIDS; 2009 Jul 31; 23(12):1531-8. PubMed ID: 19550287
    [Abstract] [Full Text] [Related]

  • 15. Disruption of the upper female reproductive tract epithelium by nonoxynol-9.
    Dayal MB, Wheeler J, Williams CJ, Barnhart KT.
    Contraception; 2003 Oct 31; 68(4):273-9. PubMed ID: 14572891
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.
    Fichorova RN, Tucker LD, Anderson DJ.
    J Infect Dis; 2001 Aug 15; 184(4):418-28. PubMed ID: 11471099
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.